AGT 181

Drug Profile

AGT 181

Alternative Names: AGT-181; cTfRMAb-IDUA murine fusion protein; HIRMAb-IDUA; IgG-alpha-L-iduronidase fusion protein; IgG-IDUA fusion protein; Recombinant human insulin receptor monoclonal antibody-fused alpha-L-iduronidase

Latest Information Update: 02 Apr 2016

Price : $50

At a glance

  • Originator ArmaGen Technologies
  • Class Immunoglobulin fusion proteins; Monoclonal antibodies
  • Mechanism of Action Iduronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mucopolysaccharidosis I

Most Recent Events

  • 01 Mar 2016 ArmaGen completes a phase I trial in Mucopolysaccharidosis I (In adults) in Brazil (IV) before March 2016
  • 01 Mar 2016 Phase-II clinical trials in Mucopolysaccharidosis I (In children) in Brazil (IV)
  • 05 Nov 2015 AGT 181 receives rare paediatric disease status for Mucopolysaccharidosis I in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top